Darzalex®▼ (daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Ineligible for Transplant
- EMEA Innovative Medicine
- Darzalex®▼ (daratumumab) Shows Overall Survival Benefit and Continued Improvement
Darzalex®▼ (daratumumab) Shows Overall Survival Benefit and Continued Improvement
- X (Twitter)
Copy link